- Email: [email protected]
Keyword Index to Volume 7
Journal of Clinical Lipidology (2013) 7, e3–e5
Keyword Index to Volume 7 A ABCA1, 109 ABCA1 gene, 82 ABCG1, 109 Abdominal obesity, 292 Achilles tendon xanthoma, 178 Adherence, 472, 574 Adiposity, 304 Adiposopathic dyslipidemia, 304 Adiposopathy, 304 Adolescents, 441 Adverse effects, 178 Age, 292 Aggression, 208 Alcohol, 454 Aortic stenosis, 683 ApoA-I, 38 APOA5 -1131T.C genotypes, 94 ApoB, 38, 626 ApoC-III, 38 APOE p.Leu167del, 566 APOE rare variants, 671 Apolipoprotein (APO) E4, 147 Apolipoprotein (apo)A-I, 169 Apolipoprotein A-I, 56 Apolipoprotein A-V concentrations, 94 Apolipoprotein B, 56 Apolipoprotein C-I, 29 Apolipoprotein E, 566 Apolipoproteins, 132, 632 Apple pectin, 140 Aspirin, 140 Atherosclerosis, 454, 561 Atorvastatin, 292 ATP-III, 43 B Bile acid sequestrants, 178 Biomarker, 433 Biovariability, 433 Body composition, 463
Cardiovascular risk, 56, 561, 626 Carotid intima media thickness, 408, 441 Central nervous system, 82 Cholesterol, 140, 165, 174, 194, 208, 472, 561, 637 Cholesterol efflux capacity, 414 Cholesterol efflux, 109 Cholesterol management, 546 Cholesterol screening, 675 Cholesterol transport, 153 Cholesteryl Ester Transfer Protein gene, 56 Cholesteryl ester transfer protein, 414 Chylomicronemia, 132 Coffee, 165 Colesevelam, 423 Compliance, 43, 472 Computerized decision support, 546 Confocal microscopy, 153 Confounder, 626 Coronary artery disease (CAD), 526 Coronary artery disease, 65, 194 Coronary disease, 637 Coronary heart disease (CHD), 169 Cost of drug therapy, 642 Cost-effectiveness analysis, 642 Cost-utility analysis, 642 Cutaneous flushing, 140 CVD, 484 Cynicism, 208
D Depression, 208 Diabetes, 38 Diagnosis, 217 Dietary cholesterol, 463 Dietary supplements, 117 Discordance, 626 Docosahexaenoic acid, 199, 615 Duplication, 174 Dyslipidemia, 14, 194, 199, 304, 423, 615, 653, 671
E C Cafe latte, 165 Campesterol, 147 Carbohydrate restriction, 463 Cardiovascular disease, 48, 484
Eggs, 463 Eicosapentaenoic acid, 199, 615 Electronic health record, 546, 573 Electronic prescribing, 573 Endothelial dysfunction, 123, 446 Environment, 65
1933-2874/$ - see front matter Ó 2013 National Lipid Association. All rights reserved.
e4
Journal of Clinical Lipidology, Vol 7, No 6, December 2013
Eosinophilic gastroenteritis, 229 Epidemiology, 208 Erythrocytes, 433 Ethnicity, 675 Euglycemic hyperinsulinemic clamp, 24 Ezetimibe/simvastatin, 292 Ezetimibe, 632
Inflammation, 123, 463 Inositol hexanicotinate, 14 Insulin resistance, 304 Insulin sensitivity, 24
F Familial, 132 Familial hypercholesterolemia, 109, 174, 217, 540, 683 Familial splenomegaly, 566 Fasting, 165 Fasting triglyceride levels, 94 Fatty acids, 123 Fenofibrate, 414, 446 Food and Drug Administration, 117 Framingham Risk Score, 194 Fructosamine, 423 G Genes, 65, 132 Genomic rearrangements, 174 Gluscose, 165 Goal attainment, 399 Guideline adherence, 637 Guidelines, 561 H Hazelnut-enriched diet, 123 HDL cholesterol, 56 HDL hypothesis, 484 HDL, 24 HDL-C, 484 Health information technology, 546, 574 Health insurance, 675 Health policy, 102 Hemoglobin A1c, 423 Heterozygous familial hypercholesterolemia, 217 High-density lipoprotein (HDL), 169, 526 High-density lipoprotein cholesterol, 414, 446, 484 High-density lipoprotein, 82, 304 High-risk, 399 HMG-CoA reductase inhibitors, 208, 637, 675 Homozygous familial hypercholesterolemia, 683 Homozygous, 540 Hostility, 208 hsCRP, 446 Hypercholesterolemia, 123, 229, 408 Hyperlipidemia, 43, 117, 147, 178, 546 Hyperlipoproteinemias, 566 Hypertriglyceridemia, 199, 566, 610, 615, 671 Hypoalbuminemia, 229 I Impaired fasting glucose, 423 India, 653 Infants and parents, 29
L LDL, 632 LDL apheresis, 109 LDL cholesterol, 165, 423 LDL oxidation, 123 LDL receptor, 174, 540 LDL receptors, 632 LDL-C, 292, 399, 540 LDL-P, 642 Left anterior descending coronary artery (LAD), 526 Lifestyle therapies, 561 Lipid lowering medications, 675 Lipid panel, 165 Lipid-lowering drugs, 169 Lipids, 102, 441 Lipoprotein heterogeneity, 29, 454 Lipoprotein lipase, 132, 454, 610 Lipoprotein(a) [Lp(a)], 526 Lipoprotein, 454, 642 Lipoproteins, 132, 441, 561, 632, 661 Low density lipoprotein, 446 Low-density lipoprotein (LDL), 169, 526 Low-density lipoprotein cholesterol, 484, 546, 574 Low-density lipoprotein, 43, 304 M Macrophage cholesterol efflux, 661 Managed care, 399 Metabolic syndrome, 65, 292, 463, 661 MicroRNA, 610 Monotherapy, 399 Multivariate analysis, 292 Muscle pain, 187 Muscle symptoms, 472 Myalgia, 187, 472 Myocardial infarction, 24 N n-3 Fatty acids, 433 National Cholesterol Educational Program Adult Treatment Panel, 43 National Lipid Association, 484 NCDs, 653 Niacin, 140, 178, 414, 423 Nicotinic acid, 14 Niemann-Pick Disease Type B sphingomyelin, 153 No-flush niacin, 14 Non-HDL cholesterol, 56 Non-HDL-C, 292, 484, 626 Non-high-density lipoprotein, 43 Noninvasive endothelial function assessments, 446 NPC1L1, 147 Number and size of LDL and HDL particles, 29
Journal of Clinical Lipidology, Vol 7, No 6, December 2013 O Obesity, 304, 661 Omega-3 fatty acid, 199, 615 Orlistat, 132 Outcomes research, 102 P Pediatrics, 408, 441 Peripheral neuropathy, 82 Pharmacology, 632 Physical performance, 187 Plasma, 433 Population management, 546 Postprandial lipemia, 48 Premature atherosclerosis, 683 Prevalence, 653 Prevention, 217 Primary health care, 637 Protein-losing enteropathy, 229
e5 Splenomegaly, 566 SR-BI, 109 Statin therapy, 102, 642 Statin, 472, 574 Statins, 117, 399, 408, 561 Strength, 187 T
Quality improvement, 546
TAK-085, 199, 615 Tangier disease, 82 Target LDL level, 43 Target non-HDL level, 43 99m Technetium diethylenetriamine-pentaacetic acid scintigraphy, 229 Therapy, 178, 217 Thromboembolism, 48 Treatment changes, 399 Triglyceride (TG), 526 Triglyceride, 446 Triglycerides, 304, 454 Type 2 diabetes mellitus, 194, 304 Type 2 diabetes, 65, 441 Type III hyperlipidemia, 671
R
U
Race, 675 Receptors, 632 Red yeast rice, 117 Resequencing, 610, 671 Resettlement colony, 653 Reverse cholesterol transport, 178 Rhabdomyolysis, 102 Right coronary artery (RCA), 526 Risk factors, 38, 48, 653
Ubiquinone, 187 Urban, 653
S
W
Secondary prevention, 637 Side effects, 472 Simvastatin, 187 Sitosterol, 147 Smoking, 454 Sphingomyelin Phosphodiesterase 1 gene, 153 Sphingomyelinase, 153
Wax-matrix extended-release niacin, 14 Weight loss, 661 WHO STEPS, 653
Q
V Vascular cell adhesion molecule-1, 446 Vascular disease, 441 Venous, 48 Vitamin E, 123
X Xanthomas, 683
Keyword Index to Volume 7 A ABCA1, 109 ABCA1 gene, 82 ABCG1, 109 Abdominal obesity, 292 Achilles tendon xanthoma, 178 Adherence, 472, 574 Adiposity, 304 Adiposopathic dyslipidemia, 304 Adiposopathy, 304 Adolescents, 441 Adverse effects, 178 Age, 292 Aggression, 208 Alcohol, 454 Aortic stenosis, 683 ApoA-I, 38 APOA5 -1131T.C genotypes, 94 ApoB, 38, 626 ApoC-III, 38 APOE p.Leu167del, 566 APOE rare variants, 671 Apolipoprotein (APO) E4, 147 Apolipoprotein (apo)A-I, 169 Apolipoprotein A-I, 56 Apolipoprotein A-V concentrations, 94 Apolipoprotein B, 56 Apolipoprotein C-I, 29 Apolipoprotein E, 566 Apolipoproteins, 132, 632 Apple pectin, 140 Aspirin, 140 Atherosclerosis, 454, 561 Atorvastatin, 292 ATP-III, 43 B Bile acid sequestrants, 178 Biomarker, 433 Biovariability, 433 Body composition, 463
Cardiovascular risk, 56, 561, 626 Carotid intima media thickness, 408, 441 Central nervous system, 82 Cholesterol, 140, 165, 174, 194, 208, 472, 561, 637 Cholesterol efflux capacity, 414 Cholesterol efflux, 109 Cholesterol management, 546 Cholesterol screening, 675 Cholesterol transport, 153 Cholesteryl Ester Transfer Protein gene, 56 Cholesteryl ester transfer protein, 414 Chylomicronemia, 132 Coffee, 165 Colesevelam, 423 Compliance, 43, 472 Computerized decision support, 546 Confocal microscopy, 153 Confounder, 626 Coronary artery disease (CAD), 526 Coronary artery disease, 65, 194 Coronary disease, 637 Coronary heart disease (CHD), 169 Cost of drug therapy, 642 Cost-effectiveness analysis, 642 Cost-utility analysis, 642 Cutaneous flushing, 140 CVD, 484 Cynicism, 208
D Depression, 208 Diabetes, 38 Diagnosis, 217 Dietary cholesterol, 463 Dietary supplements, 117 Discordance, 626 Docosahexaenoic acid, 199, 615 Duplication, 174 Dyslipidemia, 14, 194, 199, 304, 423, 615, 653, 671
E C Cafe latte, 165 Campesterol, 147 Carbohydrate restriction, 463 Cardiovascular disease, 48, 484
Eggs, 463 Eicosapentaenoic acid, 199, 615 Electronic health record, 546, 573 Electronic prescribing, 573 Endothelial dysfunction, 123, 446 Environment, 65
1933-2874/$ - see front matter Ó 2013 National Lipid Association. All rights reserved.
e4
Journal of Clinical Lipidology, Vol 7, No 6, December 2013
Eosinophilic gastroenteritis, 229 Epidemiology, 208 Erythrocytes, 433 Ethnicity, 675 Euglycemic hyperinsulinemic clamp, 24 Ezetimibe/simvastatin, 292 Ezetimibe, 632
Inflammation, 123, 463 Inositol hexanicotinate, 14 Insulin resistance, 304 Insulin sensitivity, 24
F Familial, 132 Familial hypercholesterolemia, 109, 174, 217, 540, 683 Familial splenomegaly, 566 Fasting, 165 Fasting triglyceride levels, 94 Fatty acids, 123 Fenofibrate, 414, 446 Food and Drug Administration, 117 Framingham Risk Score, 194 Fructosamine, 423 G Genes, 65, 132 Genomic rearrangements, 174 Gluscose, 165 Goal attainment, 399 Guideline adherence, 637 Guidelines, 561 H Hazelnut-enriched diet, 123 HDL cholesterol, 56 HDL hypothesis, 484 HDL, 24 HDL-C, 484 Health information technology, 546, 574 Health insurance, 675 Health policy, 102 Hemoglobin A1c, 423 Heterozygous familial hypercholesterolemia, 217 High-density lipoprotein (HDL), 169, 526 High-density lipoprotein cholesterol, 414, 446, 484 High-density lipoprotein, 82, 304 High-risk, 399 HMG-CoA reductase inhibitors, 208, 637, 675 Homozygous familial hypercholesterolemia, 683 Homozygous, 540 Hostility, 208 hsCRP, 446 Hypercholesterolemia, 123, 229, 408 Hyperlipidemia, 43, 117, 147, 178, 546 Hyperlipoproteinemias, 566 Hypertriglyceridemia, 199, 566, 610, 615, 671 Hypoalbuminemia, 229 I Impaired fasting glucose, 423 India, 653 Infants and parents, 29
L LDL, 632 LDL apheresis, 109 LDL cholesterol, 165, 423 LDL oxidation, 123 LDL receptor, 174, 540 LDL receptors, 632 LDL-C, 292, 399, 540 LDL-P, 642 Left anterior descending coronary artery (LAD), 526 Lifestyle therapies, 561 Lipid lowering medications, 675 Lipid panel, 165 Lipid-lowering drugs, 169 Lipids, 102, 441 Lipoprotein heterogeneity, 29, 454 Lipoprotein lipase, 132, 454, 610 Lipoprotein(a) [Lp(a)], 526 Lipoprotein, 454, 642 Lipoproteins, 132, 441, 561, 632, 661 Low density lipoprotein, 446 Low-density lipoprotein (LDL), 169, 526 Low-density lipoprotein cholesterol, 484, 546, 574 Low-density lipoprotein, 43, 304 M Macrophage cholesterol efflux, 661 Managed care, 399 Metabolic syndrome, 65, 292, 463, 661 MicroRNA, 610 Monotherapy, 399 Multivariate analysis, 292 Muscle pain, 187 Muscle symptoms, 472 Myalgia, 187, 472 Myocardial infarction, 24 N n-3 Fatty acids, 433 National Cholesterol Educational Program Adult Treatment Panel, 43 National Lipid Association, 484 NCDs, 653 Niacin, 140, 178, 414, 423 Nicotinic acid, 14 Niemann-Pick Disease Type B sphingomyelin, 153 No-flush niacin, 14 Non-HDL cholesterol, 56 Non-HDL-C, 292, 484, 626 Non-high-density lipoprotein, 43 Noninvasive endothelial function assessments, 446 NPC1L1, 147 Number and size of LDL and HDL particles, 29
Journal of Clinical Lipidology, Vol 7, No 6, December 2013 O Obesity, 304, 661 Omega-3 fatty acid, 199, 615 Orlistat, 132 Outcomes research, 102 P Pediatrics, 408, 441 Peripheral neuropathy, 82 Pharmacology, 632 Physical performance, 187 Plasma, 433 Population management, 546 Postprandial lipemia, 48 Premature atherosclerosis, 683 Prevalence, 653 Prevention, 217 Primary health care, 637 Protein-losing enteropathy, 229
e5 Splenomegaly, 566 SR-BI, 109 Statin therapy, 102, 642 Statin, 472, 574 Statins, 117, 399, 408, 561 Strength, 187 T
Quality improvement, 546
TAK-085, 199, 615 Tangier disease, 82 Target LDL level, 43 Target non-HDL level, 43 99m Technetium diethylenetriamine-pentaacetic acid scintigraphy, 229 Therapy, 178, 217 Thromboembolism, 48 Treatment changes, 399 Triglyceride (TG), 526 Triglyceride, 446 Triglycerides, 304, 454 Type 2 diabetes mellitus, 194, 304 Type 2 diabetes, 65, 441 Type III hyperlipidemia, 671
R
U
Race, 675 Receptors, 632 Red yeast rice, 117 Resequencing, 610, 671 Resettlement colony, 653 Reverse cholesterol transport, 178 Rhabdomyolysis, 102 Right coronary artery (RCA), 526 Risk factors, 38, 48, 653
Ubiquinone, 187 Urban, 653
S
W
Secondary prevention, 637 Side effects, 472 Simvastatin, 187 Sitosterol, 147 Smoking, 454 Sphingomyelin Phosphodiesterase 1 gene, 153 Sphingomyelinase, 153
Wax-matrix extended-release niacin, 14 Weight loss, 661 WHO STEPS, 653
Q
V Vascular cell adhesion molecule-1, 446 Vascular disease, 441 Venous, 48 Vitamin E, 123
X Xanthomas, 683